NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • Getting involved with research
    • Researcher Guidance
    • Post an opportunity for patient and public involvement
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Preparatory Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > COVID-19 > MAIT Cell activation may play role in COVID-19 deaths, study finds

MAIT Cell activation may play role in COVID-19 deaths, study finds

17 September 2021 · Listed under COVID-19, Gastroenterology and Mucosal Immunity

Oxford researchers have found a correlation between deaths from COVID-19 infections and a poorly coordinated systemic immune response, as well as increased activity by Mucosal Associated Invariant T cells, or ‘MAIT cells’.

Image: Belova59 from Pixabay 

A study involving Oxford BRC-supported researchers published in PLOS Pathogens suggests there is a link between inflammatory responses in the body and increased mortality.

In humans, MAIT cells are a kind of white blood cell that helps defend the body against microbial activity and infection.

The mortality rate of COVID-19 patients requiring mechanical ventilation is 30-40 per cent. However, the immunological factors associated with death in critically ill COVID-19 patients are poorly understood.

Antibodies and T cells play a critical role in protecting the body from viral illness, but their exact role in responding to SARS-CoV-2 infection is unclear.

To better understand the immune abnormalities linked to critical illness and death in COVID-19 patients on ICU, researchers conducted a prospective observational study investigating the association of T cell and antibody responses with death in severe COVID-19.

They analysed blood samples from 41 COVID-19 patients who were being ventilated mechanically, carrying out immunophenotyping of T cell responses and a range of experiments analysing antibody responses.

They then compared their findings to a parallel set of 18 mechanically ventilated influenza patients, as well as to 12 patients with mild COVID-19 and 12 healthy controls.

The researchers, who include the Oxford BRC’s Co-theme Lead for Gastroenterology and Mucosal Immunity, Prof Paul Klenerman, found that fatal COVID-19 infections were correlated with poorly coordinated systemic immune responses, and an increased activation of MAIT cells was the strongest predictor of a fatal outcome.

The authors said: “Our study yields an enhanced understanding of the differential immunopathogenic processes driving critical COVID-19 and influenza, which can translate into improved immunotherapeutic approaches in patients with severe viral pneumonitis.”

They added: “In critically ill patients on ICU with COVID-19 and influenza, an unbiased analysis of the antiviral immune response revealed activation of a specific immune subset -Mucosal-associated invariant T (MAIT) cells – as a strong immunological predictor of death.”

“Survival in critical COVID-19 is associated with focused immune responses driven mainly by one cytokine – interferon alpha – in contrast to the very broad pro-inflammatory responses seen in those with fatal disease. This cytokine pattern linked to death versus survival separates critical COVID-19 from influenza.”

← Study investigates responses to COVID-19 treatment in chronic lymphoid leukaemia patients
Moonshot initiative to develop affordable COVID-19 antivirals gets funding boost →

News

  • Study highlights ongoing COVID-19 risk in some cancer patients despite vaccination 24 May 2022
  • BRC study outlines researchers training needs and barriers 20 May 2022
  • Three new Blood and Transplant Research Units created in Oxford 18 May 2022
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2022 NIHR Oxford Biomedical Research Centre